[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medical University of Lublin\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":225},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,82,110,142,165,191],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100599499","perfusion-related-evaluation-of-systemic-and-renal-vulnerability-to-events-in-cabg-100599499",false,"NCT07085286","Perfusion Related Evaluation of Systemic and Renal Vulnerability to Events in CABG","Prognostic Value of Continuous Intra-abdominal Pressure (CIAP) and Continuous Abdominal Perfusion Pressure (CAPP) Monitoring for Acute Kidney Injury (AKI) Prediuction in Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery","PRESERVE-CABG","Inclusion Criteria\n\n* Age 18 years or older\n* Undergoing cardiac surgery (CABG, valve surgery, combined procedures, heart transplantation, or placement of assist device)\n* Expected hospital stay of at least one night\n* Preoperative serum creatinine measurement available\n* At least one postoperative serum creatinine measurement available\n\nExclusion Criteria\n\n* Age below 18 years\n* Incarcerated individuals\n* No requirement for urinary catheter placement\n* Presence of a do-not-resuscitate (DNR) order\n* Pregnant or lactating individuals\n* Fewer than 12 hours of recorded data (including intraoperative data)\n* No informed consent (if a waiver is not granted)\n* Pre-existing chronic kidney disease, defined as estimated glomerular filtration rate \\\u003C60 mL\u002Fmin\u002F1.73 m²","ALL","18 Years",{"count":20,"type":21},45,"ESTIMATED","6 Months","OBSERVATIONAL","The goal of this observational study is to learn whether high abdominal pressure or low blood flow pressure to the kidneys is linked to kidney injury after heart surgery. The main questions it aims to answer are:\n\nDoes high abdominal pressure increase the risk of kidney injury after cardiac surgery?\n\nCan low blood flow pressure to the kidneys help predict who may develop kidney problems?\n\nParticipants in this study are adults undergoing heart surgery, such as coronary artery bypass grafting (CABG) or valve surgery. Researchers will measure abdominal pressure and blood pressure continuously before and after surgery using medical devices that are already part of routine care. This study does not involve any changes to standard treatment.\n\nParticipants will:\n\nHave their abdominal and blood pressures continuously monitored using existing devices\n\nHave blood and urine tests to check kidney function\n\nBe followed during their hospital stay and up to 30 days after surgery to assess outcomes like length of stay, readmission, and survival\n\nThis study takes place at two hospitals-one in Poland and one in the United States. Researchers hope the findings will help identify early warning signs of kidney injury and improve monitoring practices after heart surgery.",[26,27],"AKI - Acute Kidney Injury","CABG",[29,30,31,32,33,34,35],"abdominal pressure","IAP","abdominal perfusion pressure","mean perfusion pressure","renal perfusion pressure","prediction","AKI","NOT_YET_RECRUITING","2025-07-17",{"date":39,"type":40},"2025-07-25","ACTUAL",{"date":42,"type":21},"2026-01-01",{"date":44,"type":21},"2026-12-31",{"name":46,"class":47},"Medical University of Lublin","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},"100533395","phase-2-xanthohumol-as-an-adjuvant-in-the-treatment-of-septic-shock-100533395","NCT06225258","Xanthohumol as an Adjuvant in the Treatment of Septic Shock","Analysis of Anti-inflammatory Effect of Hop Extract Rich in Xanthohumol in Patients Treated for Septic Shock","Inclusion Criteria:\n\n* a septic shock in the early, acute phase,\n* respiratory insufficiency required mechanical ventilation with PaO2\u002FFiO2 \\\u003C 150,\n* bacterial infection,\n* procalcitonin higher than 5 ng\u002FmL and interleukin 6 higher than 100 pg\u002FmL,\n* no allergy to hops or their derivatives,\n* hemodynamic instability requiring vasopressor infusions\n\nExclusion Criteria:\n\n* lack of agreement\n* septic shock treated for more than 1 day,\n* history of severe chronic cardiac, pulmonary and\u002For liver diseases",{"count":56,"type":21},50,"INTERVENTIONAL",[59],"PHASE2","Septic shock (SS) is a life-threatening condition resulting from excessive inflammatory response to bacterial, viral or\u002Fand fungal infections. It is associated with dysregulation of the immune system, activation of immune cells, and massive release of cytokines, commonly known as the cytokine storm (CS). The clinical manifestations of SS depend on the initial site of infection. However, the classic symptoms are associated with severe dysfunction of the respiratory and cardiovascular systems, which are observed from the early phase. Respiratory insufficiency frequently requires different forms of oxygen supplementation, including mechanical ventilation and even extracorporeal oxygenation. The severity of respiratory and other organ dysfunction depends on the inflammatory response to the infection and circulating toxins, which correspond to excessive cytokine release. In the past years, several studies documented that reduction of SS-related inflammatory response and CS improved organ function and alleviated the clinical course of SS. Unfortunately, an effective strong anti-inflammatory without side effects medications has not yet been found. Therefore, the use of natural anti-inflammatory and antioxidant substances seems very promising.\n\nXanthohumol (Xn) is a natural prenylated chalcone extracted from the female inflorescences of hop cones (Humulus lupus) and possesses strong anti-inflammatory and antioxidant properties. It is widely used as a supplement to diet. Xanthohumol inhibits CS and has been showed to be an effective medication for reducing the severity of lung injury. It has been documented that Xn inhibits proinflammatory pathways in a different manner. A decrease in cytokine production and release can affect endothelial function and correct inflammatory-related vascular hyperpermeability, reducing uncontrolled water shift to extravascular space and then tissue edema. Clinical observation showed that administration of Xn alleviated clinical course, improved respiratory function, and reduced mortality in critically ill COVID-19 patients. Xanthohumol is safe and well tolerated by humans, and no adverse effects have been reported yet. Based on its strong anti-inflammatory and antioxidative properties, it can be speculated that the use of Xn can effectively reduce the inflammatory response and improve the clinical course in SS patients.",[62,63,64],"Septic Shock","Pneumonia","ARDS",[66,67,68,69,70,64,71],"septic shock","inflammation","Xanthohumol","adjuvant","endotheliopathy","cytokine","RECRUITING","2025-07-01",{"date":75,"type":40},"2025-07-04",{"date":77,"type":40},"2023-01-09",{"date":79,"type":21},"2025-12-31",{"name":46,"class":47},1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":90,"sex":91,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":4},"100585059","characterization-of-immune-cells-and-their-secreted-cytokines-in-endometriosis-patients-100585059","NCT06897436","Characterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients","\"EUmetriosis: Transforming Endometriosis Care in Europe: an Integrated Approach to Enhance Understanding, Diagnosis, Tailored Management and Patient Empowerment","EUmetriosis","Inclusion Criteria:\n\n* Women with a clinical and\u002For ultrasound diagnosis of endometriosis who are candidates for surgery\n* Age between 18 and 50 years\n* Pre-menopausal status\n* Experiencing regular menstruation\n* Willing to collect menstrual effluent\n* Signature of informed consent to the study\n\nExclusion Criteria:\n\n* Age below 18 years\n* Post-Menopausal status\n* Presence of Crohn's disease\n* Presence of Ulcerative Colitis\n* Presence of short bowel syndrome or another chronic inflammatory disease\n* Use immunosuppressive medication\n* Receiving contraceptive hormone therapy\n* Pregnant\n* Presence\u002Fhistory of malignancy",true,"FEMALE","40 Years",{"count":94,"type":21},60,"The EUmetriosis project aims to address the most important unmet needs of endometriosis sufferers to advance patient care. The objectives cover all main aspects of disease management, including elucidating the pathogenesis, diagnosing the condition promptly and efficiently, facilitating care by implementing self-management strategies, raising awareness and promoting policy changes. The objectives comprise individual yet intersecting pieces of a puzzle which, when positioned correctly, can immensely improve disease perception and understanding to enhance patient care. The project will prioritise the needs and wants of modern-day patients, focused on providing easily accessible and noninvasive therapeutic options. Combining all these elements in a well-coordinated project is pivotal to relieving the heavy burden endometriosis places on European society as a whole.",[97],"Endometriosis",[99,100,101],"endometriosis","dermoid cyst","immune system","2025-03-24",{"date":104,"type":40},"2025-03-27",{"date":106,"type":21},"2025-05-01",{"date":108,"type":21},"2029-12-31",{"name":46,"class":47},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":57,"phases":119,"briefSummary":121,"conditions":122,"keywords":128,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":141},"100555803","diluted-and-undiluted-enteral-nutrition-100555803","NCT06516835","Diluted and Undiluted Enteral Nutrition","The Influence of Diluted and Undiluted Enteral Nutrition on Nutritional Tolerance in Critically Ill Patients After Gastrointestinal Surgery - a Randomized Controlled Trial","Inclusion Criteria:\n\n* Scheduled for major abdominal surgery requiring ICU admission\n* Having access to the GI tract (gastric or jejunal)\n* Planned to be fed enterally\n\nExclusion Criteria:\n\n* Patients unable to give informed consent\n* After emergency surgeries\n* Without access to the GI tract\n* Individuals with contraindications to EN, such as short bowel syndrome, uncompensated shock, acidosis (pH \\\u003C 7.1; lactate \\> 5 mmol\u002Fl), bleeding from the upper GI tract, obstruction, intestinal ischemia, abdominal compartment syndrome\n* Patients with symptomatic gastro-esophageal reflux\n* Expected ICU stay \\\u003C 3 days\n* Pregnancy and lactation","80 Years",{"count":94,"type":21},[120],"NA","Adult patients after elective major abdominal surgeries who are planned to be admitted to the Intensive Care Unit (ICU) can be included in the trial.\n\nEach patient will be fed via the gastrointestinal tract. Half of the patients will receive enteral nutrition (EN) with additional fluids, and the rest will receive undiluted EN.\n\nThe primary aim of this study is feeding intolerance assessment in both groups of patients.",[123,124,125,126,127],"Critical Illness","Surgery","Enteral Feeding Intolerance","Gastro-Intestinal Disorder","Quality of Life",[129,130,131,132],"Zonulin","Intestinal fatty-acid binding protein (I-FABP)","Ketones","Microbiome","2024-07-24",{"date":135,"type":40},"2024-07-26",{"date":137,"type":21},"2025-01-02",{"date":139,"type":21},"2027-04-30",{"name":46,"class":47},5,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":90,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":150,"conditions":151,"keywords":154,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":81},"100549906","relationship-between-circulating-sclerostin-and-bone-lesions-in-patients-with-mastocytosis-100549906","NCT06440148","Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis","Role of Sclerostin in Mastocytosis Bone Disease","Inclusion Criteria:\n\n* Age \\> 18 years\n* Mastocytosis defined according to WHO criteria\n* Known KIT mutation status\n\nExclusion Criteria:\n\n* History of organ transplant\n* Inability to give informed consent\n* Pregnancy, Breastfeeding\n* Vulnerable Patient, defined as: patient with another uncontrolled severe disease; patient under juridical protection",{"count":56,"type":21},"Mastocytosis is very rare and highly heterogeneous group of disorders, characterized by the accumulation of clonal mast cells which can infiltrate several organs and tissues.\n\nBones are the most frequent localization of systemic mastocytosis. The aim of our research was to explain the potential role of sclerostin in the pathogenesis of bone disease in mastocytosis.",[152,153],"Mastocytosis","Bones",[153,152,155,156,157],"Osteolysis","Osteosclerosis","Sclerostin","2024-05-28",{"date":160,"type":40},"2024-06-03",{"date":162,"type":40},"2019-09-01",{"date":44,"type":21},{"name":46,"class":47},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":91,"minAge":18,"maxAge":172,"enrollmentInfo":173,"targetDuration":4,"studyType":57,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":190,"locationsCount":81},"100512658","phase-2-effectiveness-of-low-dose-naltrexone-in-patients-with-different-types-of-vulvodynia-100512658","NCT05955313","Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia","Effectiveness of Low-doses of Naltrexone (LDN) on Pain Perception and Quality of Life in Women With Vulvodynia","Inclusion Criteria:\n\n1. Women from the age of 18 to the menopause or to the age of 50 (on the day of inclusion for testing).\n2. Patients who are not pregnant and do not plan to become pregnant in the next 9 months from the inclusion in the study\n3. Signing the patient's informed and voluntary consent to participate in the study.\n4. General health of the patient (WHO = 0-2).\n5. Diagnosis of vulvodynia.\n6. Negative drug test found at the visit randomization.\n7. Documented correct cytology result from 3 years ago (before the visit screening).\n8. Stable dose of drugs acting on the central nervous system used min. 1 month before the screening visit and during the entire patient's participation in the study.\n9. Acceptance or readiness to use a highly effective method of contraception from the screening visit throughout the study. Sexual abstinence is not accepted.\n10. The ability to understand the principles of testing and operating electronic devices.\n\nExclusion Criteria:\n\n1. Severe, hepatic and renal dysfunction defined as:\n\n   i. An ASPT or ALT result 5 times the upper limit; ii. The level of bilirubin 3 times above the upper limit of normal - excluding patients with Gilbert's syndrome; iii. EGFR result below 30 ml \u002F min \u002F m2, on the basis of historical studies not older than 3 years before the screening visit or from the tests performed during the screening visit according with point 12 of the Protocol, version 1.0 of March 28, 2022.\n2. Abuse of alcohol (more than 14 units per week) and other stimulants. 3. Taking psychoactive substances, including drugs, except for SSRI, SNRI, SARI (Trazodone), and anticonvulsants (Gabapentin, Pregabalin, Lamotrigine) in fixed doses from the screening visit.\n\n4\\. Taking opioid drugs in the last 2 months before the screening visit (also in OTC preparations, eg Loperamide).\n\n5\\. Taking naltrexone hydrochloride and Mysimba for weight loss at any time in your life.\n\n6\\. BTA injection in the vulva in the last 4 months before the screening visit. 7. Endovascular procedures in the area of the small pelvis in the last 6 months before the screening visit.\n\n8\\. Previous surgical procedures requiring general anesthesia (with general anesthesia) in the last 2 months before the screening visit.\n\n9\\. Completed multidisciplinary therapeutic program in the treatment of vulvodynia in the last 4 months before the screening visit.\n\n10\\. Diseases of the vulva: lichen, current contact vulvovaginitis, bacterial and \u002F or yeast infections, other dermatological diseases, recurrent genital herpes (HSV; min 4 times \u002F year).\n\n11\\. Diagnosis of current or past serious mental disorders according to the criteria of ICD-10 and DSM-5, including psychotic and organic disorders (except depression and anxiety disorders).\n\n12\\. Gynecological abnormalities requiring medical treatment: current HSIL, CIN II \u002F III, pelvic inflammation, mixed or solid ovarian tumors, simple ovarian cysts greater than 5 cm, abnormal vaginal inter-cycle bleeding.\n\n13\\. Pelvic venous diseases (PeVD), 4 criteria met on USG. 14. Pregnancy and lactation. 15. Spastic diseases: multiple sclerosis (MS), connective tissue diseases (Marfan syndrome and marfan-like syndromes), reactive arthritis (RA). 16. Vaginismus, Lamont scale 3-5 (gynecological examination impossible due to anxiety).\n\n17\\. Significant and \u002F or uncorrected disability in the field of sight or hearing, making it difficult to perform psychological tests.","50 Years",{"count":174,"type":21},300,[59],"Vulvodynia (Vd) is chronic functional vulvar pain, with prevalence of 3-16% and unclear etiopathology. Although Vd significantly deteriorates quality of life, the problem is marginalized, no pharmacologic treatment standards exist. Naltrexone hydrochloride is a specific opioid antagonist with slight agonist activity. There is growing body of evidence supporting the effectiveness of low-dose naltrexone (LDN) in different types of chronic pain. The main goal of this trial is to test the effect of LDN on pain perception and quality of life in women with different types of Vd. Half of the study population receives LDN and the remaining patients take placebo, according to randomization list. This RTC is quadruplet blinded.",[178,179,127],"Vulvodynia","Naltrexone",[181,182,183],"vulvodynia","low dose naltrexone","quality of life","2023-07-12",{"date":186,"type":40},"2023-07-21",{"date":188,"type":40},"2023-05-31",{"date":44,"type":21},{"name":46,"class":47},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":199,"enrollmentInfo":200,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":202,"conditions":203,"keywords":208,"overallStatus":72,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":81},"100494864","malnutrition-assessment-with-bioelectrical-impedance-analysis-in-gastric-cancer-patients-undergoing-multimodal-treatment-100494864","NCT05723718","MalnutritiOn Assessment With biOelectrical impedaNce Analysis in gastRic Cancer patIentS Undergoing Multimodal trEatment","MalnutritiOn Assessment With biOelectrical impedaNce Analysis in gastRic Cancer patIentS Undergoing Multimodal trEatment - MOONRISE Study","MOONRISE","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Histologically confirmed gastric adenocarcinoma (or undifferentiated carcinoma)\n3. Stage II - III disease (cT2 cN+ and cT3-T4 cN+\u002F-) based on the 8th edition of TNM classification\n4. Qualification for multimodal treatment by the decision of the multidisciplinary tumor board\n\nExclusion Criteria:\n\n1. Early gastric cancer (cT1N0-3M0) scheduled for endoscopic treatment by multidisciplinary team\n2. Gastric stump carcinoma\n3. Distant metastasis\n4. Upfront surgery\n5. Other malignancies\n6. Contraindications to bioelectrical impedance analysis (e.g., implanted cardiac devices, metal implants or pregnancy)","100 Years",{"count":201,"type":21},125,"The aim of this single-arm prospective, multicenter, cross-sectional study is to evaluate the nutritional status and body composition on tumor regression grade with bioelectrical impedance analysis in gastric cancer patients undergoing multimodal treatment. Results of this study will reveal whether nutritional status and body composition assessment based on bioelectrical impedance analysis will become a validated and objective tool to support clinical decisions in gastric cancer patients undergoing multimodal treatment.",[204,205,206,207],"Gastric Cancer","Gastric Adenocarcinoma","Malnutrition","Cachexia",[209,210,211,212,213,214,215,216],"gastric cancer","bioelectrical impedance analysis","body composition","nutritional status","malnutrition","cachexia","multimodal treatment","tumor regression grade","2023-02-09",{"date":219,"type":40},"2023-02-13",{"date":221,"type":40},"2022-12-20",{"date":223,"type":21},"2028-12-31",{"name":46,"class":47},""]